Gilead Sciences has agreed to acquire biotechnology company Arcellx in an all-cash transaction valued at approximately $7.8 billion, or $115 per share, according to a definitive agreement announced today. The offer represents a 68% premium to Arcellx's 30-day volume-weighted average price and includes an additional contingent value right of $5 per share contingent on anito-cel, Arcellx's investigational CAR-T cell therapy, achieving $6 billion in cumulative global net sales by the end of 2029.
The acquisition consolidates Gilead's existing collaboration with Arcellx on the BCMA-directed CAR-T cell therapy designed to treat multiple myeloma patients. The strategic combination positions Gilead to strengthen its oncology pipeline and expand its cell therapy capabilities, leveraging Arcellx's proprietary technology platform alongside Gilead's established commercial and development infrastructure.
The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions and regulatory approvals. The deal marks a significant expansion of Gilead's commitment to cell therapy innovation, a therapeutic area representing considerable growth opportunity within the broader immuno-oncology market.